

An Impressive achievement for Allium Medical:

Allium received an FDA approval for its innovative EndoFast Reliant SCP device

This approval is particularly important in light of the growing global trend of treating Pelvic Organ Prolapse by the minimally invasive laparoscopic approach

Israel, Caesarea, July 31, 2013: Allium Medical Solutions Ltd. (TASE: ALMD), a medical device company engaged in minimally invasive technologies, announced today of an impressive achievement of receiving an FDA approval for the EndoFast Reliant SCP that is indicated for Pelvic Organ Prolapse Repair and soft tissue fixation by a laparoscopic approach (minimally invasive abdominal approach).

Asaf Alperovitz, CEO of Allium Medical noted: "we are happy that another important product of ours was approved for marketing in the US and this is a significant milestone for us. Receiving the approval in a relatively short period further demonstrates our ability to commercialize technologies and IP. We believe that our product, which presents clear clinical advantages, will create value for patients, physicians, health systems, insurers and to our company shareholders. The EndoFast Reliant SCP, which is indicated for minimally invasive abdominal procedures, utilizes the company's unique proprietary Spider Fastener technology and enables optimal fixation with shallow penetration, usage of low number of fasteners and a significant reduction of the risk for blood vessels or tissue injury. In this way, we can achieve better and safer results, faster patient recovery while leaving less foreign bodies. The company's innovative device allows optimal fixation in comparison to competitive devices. Additionally, Allium's products provide to both the physician and patient to choose between two different minimally invasive treatment approaches.

Treating pelvic Organ Prolapse by the laparoscopic approach is gaining significant momentum in the global markets that we expect to further increase in the coming years. We believe that with our unique products we are best positioned to compete in this market.

Receiving the FDA approval for an additional product of the EndoFast Reliant product line for Pelvic Organ Prolapse is the result of the successful implementation of Allium's business strategy of leveraging the Company's unique Spider Fastener platform technology.

The unique Fastener for soft tissue fixation can be used in additional applications while expanding our technology potential markets. Following the FDA approval, the Company intends to manufacture the EndoFast Reliant SCP in controlled production series for clinical and commercial purposes.

This approval follows another FDA approval received on April 2008 for the EndoFast Reliant System used for Pelvic Organ Prolapse which is based on company's innovative technology for soft tissue fixation.

The Spider Fastener is the key to the EndoFast Reliant product line efficiency in treatment of Pelvic Organ Prolapse repair in the fields of Urology and Gynecology. Its design and components are based on our proprietary technology and creates unique features: strong attachment to soft tissue, durability, retrievability after attachment and optimal tissue integration.

The EndoFast Reliant SCP is based on the Spider Fastener of the EndoFast Reliant System (in different size and different package). The laparoscopic package contains 3 disposable fixation devices (one extra) and 1 disposable handle (to which the fixation devices are inserted).

About Allium Medical Solutions Ltd:

Allium Medical Solutions Ltd. recently completed extensive strategic transactions including two acquisitions (by way of shares exchange) of companies synergetic to Allium's activities – Gardia Medical Ltd. and IBI Israel Biomedical Innovations Ltd. Following such synergetic acquisitions, the Company generated a critical mass in minimally invasive technologies and is currently working with three attractive product lines in the fields of urology (stents - Allium®Stents), gynecology (IBI - EndoFast ®) and minimally invasive interventional procedures (Gardia-EPD).

Allium specializes in minimally invasive medical devices and owns a variety of technologies and product lines in this field. The company's strategy is to create value by expanding internal developments as well as acquisition of additional products and technologies. The company is lead by professionals with extensive knowledge and vast experience in taking products from R&D to market while insuring a long term financing and the advantage of size.

The Group's Websites:

www.allium-medical.com

www.ibimedical.com

www.gardiamedical.com